TREM2 Human, HEK
HEK293 Cells.
Greater than 95.0% as determined by SDS-PAGE.
Description
TREM2 Human Recombinant is a single, glycosylated, polypeptide chain (19-174 a.a) containing a total of 162 amino acids, having a molecular mass of 18.2 kDa.
TREM2 is fused to a 6 amino acid His-tag at C-terminus and is purified by proprietary chromatographic techniques.
Product Specs
Recombinant human TREM2 is a glycosylated polypeptide chain consisting of amino acids 19-174. It has a molecular weight of 18.2 kDa and includes a 6-amino acid His-tag at the C-terminus. The protein is purified using proprietary chromatographic techniques.
The TREM2 solution has a concentration of 1 mg/ml and is formulated in a solution of phosphate-buffered saline (pH 7.4) containing 10% glycerol.
For short-term storage (up to 4 weeks), the TREM2 solution can be stored at 4°C. For extended storage, it is recommended to freeze the solution at -20°C. Adding a carrier protein like HSA or BSA (0.1%) is advisable for long-term storage. Repeated freezing and thawing should be avoided.
Analysis by SDS-PAGE has determined the purity of this product to be greater than 95%.
HEK293 Cells.
HNTTVFQGVA GQSLQVSCPY DSMKHWGRRK AWCRQLGEKG PCQRVVSTHN LWLLSFLRRW NGSTAITDDT LGGTLTITLR NLQPHDAGLY QCQSLHGSEA DTLRKVLVEV LADPLDHRDA GDLWFPGESE SFEDAHVEHS ISRSLLEGEI PFPPTSHHHH HH.
Product Science Overview
Genetic variants and mutations in TREM2 are associated with various neurodegenerative diseases. Homozygous mutations in TREM2 can lead to early-onset progressive presenile dementia, while heterozygous point mutations significantly increase the risk of Alzheimer’s disease . TREM2 is involved in several key cellular processes, including:
- Phagocytosis: TREM2 promotes the engulfment and clearance of apoptotic cells and amyloid plaques, which is essential for maintaining tissue homeostasis .
- Cell Survival: Activation of TREM2 triggers signaling pathways such as the PI3K-Akt pathway and spleen tyrosine kinase (Syk), promoting cell survival and proliferation .
- Cytokine Production: TREM2 activation leads to the production of cytokines, which are critical for the immune response .
TREM2 has garnered significant attention for its role in Alzheimer’s disease. The receptor is involved in the survival and activation of microglia, the brain’s resident immune cells. Microglia play a pivotal role in the clearance of amyloid-beta plaques, a hallmark of Alzheimer’s disease . Studies have shown that TREM2 activation can ameliorate amyloid-beta deposition and improve cognitive function in animal models of Alzheimer’s disease .
Given its central role in neuroinflammation and neurodegeneration, TREM2 is considered a promising therapeutic target. Agonistic antibodies targeting TREM2 have been developed to enhance its activity and promote the clearance of amyloid plaques. These therapeutic strategies aim to harness the protective functions of TREM2 to mitigate the progression of neurodegenerative diseases .
Human recombinant TREM2 (produced in HEK cells) is widely used in research to study its structure, function, and therapeutic potential. The recombinant protein allows for detailed biochemical and biophysical analyses, facilitating the development of targeted therapies.
